Home » Stocks » ORMP

Oramed Pharmaceuticals Inc. (ORMP)

Stock Price: $5.53 USD 0.95 (20.74%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $5.80 +0.27 (4.88%) Jan 22, 7:57 PM
Market Cap 147.44M
Revenue (ttm) 2.71M
Net Income (ttm) -14.54M
Shares Out 23.75M
EPS (ttm) -0.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $5.53
Previous Close $4.58
Change ($) 0.95
Change (%) 20.74%
Day's Open 4.63
Day's Range 4.60 - 5.70
Day's Volume 1,703,428
52-Week Range 2.48 - 5.70

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 2 days ago

NEW YORK, Jan. 21, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral dru...

PRNewsWire - 2 weeks ago

NEW YORK, Jan. 7, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug...

PRNewsWire - 1 month ago

NEW YORK, Dec. 23, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral dru...

PRNewsWire - 1 month ago

NEW YORK, Dec. 2, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug...

PRNewsWire - 2 months ago

NEW YORK, Nov, 24, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delive...

PRNewsWire - 2 months ago

NEW YORK, Nov. 12, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delive...

PRNewsWire - 2 months ago

NEW YORK, Oct. 28, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral dru...

PRNewsWire - 3 months ago

NEW YORK, Oct. 16, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral dru...

PRNewsWire - 4 months ago

NEW YORK, Sept. 21, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral dr...

PRNewsWire - 4 months ago

NEW YORK, Sept. 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc.

PRNewsWire - 4 months ago

NEW YORK, Sept. 3, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc.

GuruFocus - 6 months ago

Pharmaceutical companies have poured millions—maybe billions—of dollars into research aimed at finding a way to deliver insulin to patients by mouth.

PRNewsWire - 7 months ago

NEW YORK, June 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral dru...

About ORMP

Oramed Pharmaceuticals engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight... [Read more...]

Industry
Biotechnology
Founded
2002
CEO
Nadav Kidron
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
ORMP
Full Company Profile

Financial Performance

In 2020, ORMP's revenue was $2.71 million, an increase of 0.26% compared to the previous year's $2.70 million. Losses were -$11.51 million, -19.81% less than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for ORMP stock is "Strong Buy." The 12-month stock price forecast is 12.60, which is an increase of 127.85% from the latest price.

Price Target
$12.60
(127.85% upside)
Analyst Consensus: Strong Buy